Drug-coated balloon with paclitaxel for in-stent restenosis of femoral popliteal artery: initial experience in 18 patients
10.3969/j.issn.1008-794X.2017.06.016
- VernacularTitle:紫杉醇药物涂层球囊治疗股腘动脉支架内再狭窄18例
- Author:
Xupin XIE
;
Xin FANG
;
Changpin HUANG
;
Yongchang LIU
;
Dong XU
;
Jianyun LONG
;
Naigong LIN
- Keywords:
femoral popliteal artery;
in-stent restenosis;
paclitaxel;
drug-coated balloon
- From:Journal of Interventional Radiology
2017;26(6):544-547
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term effect of drug-coated balloon (DCB) with paclitaxel in treating in-stent restenosis (ISR) of femoral popliteal artery.Methods A total of 18 patients with femoral popliteal artery ISR,who were admitted to authors' hospital during the period from June 2016 to December 2016 to receive paclitaxel DCB treatment,were enrolled in this study.The patients included 15 males and 3 females,with a mean age of (72.7±9.8) years old.According to Fontaine classification,grade Ⅱ B was seen in 9 patients,grade Ⅲ in 8 patients,and grade Ⅳ in one patient.Preoperative CT angiography showed that ISR could be confirmed in 3 patients and complete occlusion of the stent in 15 patients.After the diseased artery was re-opened,pre-dilatation with common balloon was conducted,which was followed by dilatation with paclitaxel DCB;remedial stent implantation was carried out when the restrictive dissection was observed or if the residual stenosis was beyond 50％.Angiography was performed immediately after the procedure to check the vascular patency.On the third day afterthe treatment,the ankle-brachial index (ABI) of diseased lower extremity was determined to assess the improvement of ischemia.Three month after the treatment,the patients were followed up to detemine the incidence of restenosis,the clinically-driven target lesion revascularization (TLR) rate,and the occurrence of serious clinical events within 3 months.Results Successful re-opening of the diseased artery was achieved in all 18 patients,the technical success rate was 100％.At 3 months after the treatment,the restenosis rate and TLR rate were 10％ (1/10) and 6.67％ (1/15) respectively.No procedure-related complications occurred in all patients.Conclusion For the treatment of femoral popliteal artery ISR,the use of paclitaxel DCB is safe and effective.
